November 2018
Earle A. Chiles Research Institute, a division of Providence Cancer Institute in the Robert W. Franz Cancer Center, is currently conducting more than 120 research studies, including clinical trials of targeted therapies and novel immunotherapy approaches.
CAR T-cell trial offers second-line therapy for aggressive lymphoma
Patients who have relapsed or failed first-line treatment for aggressive forms of B-cell
non-Hodgkin lymphoma may qualify to receive a promising CAR T-cell therapy in a new clinical trial at Providence Cancer Institute .

The study treatment, JCAR017 , provided “a durable reduction or eradication of cancer” in a Phase I study, including complete cancer eradication in just over half of the patients.

Read more in Lymphoma News Today
All current open studies:
Find additional studies for many types of cancer in Multiple Tumor Types .
New studies are posted frequently - please check our  website  for a complete list of our current studies. For more information, call 503-215-2614.